Essential Fatty Acid Status & Immune Function in Parenteral Nutrition Patients

November 11, 2014 updated by: Geert Wanten
The purpose of this study is to determine if patients on long-term olive oil-based parenteral nutrition have an adequate essential fatty acid status and immune status, compared to age- and sex-matched healthy controls.

Study Overview

Status

Completed

Conditions

Detailed Description

Patients, who suffer from severe chronic intestinal failure and whose nutritional intake cannot be met by oral food intake, have as their final option total parenteral nutrition, which contains all necessary macro- and micronutrients. Lipid emulsions are essential for these patients as they are a source of non glucose fuel calories, and they contain (essential) fatty acids which are important as structural component for many cells in the human body. Home parenteral nutrition patients are at risk for essential fatty acid deficiency. Data are lacking that indicate the optimal amount of essential fatty acids required for these patients. The latter seems especially relevant for patients receiving lipid prescriptions which are low in essential fatty acids, like ClinOleic®. Long-term parenteral nutrition dependent patients successfully use ClinOleic®. It is however unknown whether these patient remain to have an adequate essential fatty acid status in the long run.

Study Type

Observational

Enrollment (Anticipated)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • Netherlands
      • Nijmegen, Netherlands, 6525 GA
        • Department of gastroenterology and hepatology

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

18 years to 80 years (Adult, Older Adult)

Accepts Healthy Volunteers

Yes

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

Long-term parenteral nutrition dependent patients:Patients who visit the outpatient clinic of the Department of Gastroenterology and Hepatology at the Radboud University Medical Nijmegen Center.

Healthy controls: volunteers who are residents in the Netherlands.

Description

Home parenteral nutrition patients:

Inclusion Criteria:

  • home parenteral nutrition: at least 6 months with a minimum frequency of 5 times a week

Exclusion Criteria:

  • active immune modulating (underlying) disease
  • use of immune suppressives
  • use of oral fish oil substrates
  • smoking more than 5 cigarettes/day
  • do not eat more than 5 portions of fatty fish per week

Healthy controls:

Inclusion Criteria:

  • age and sex matched healthy volunteer

Exclusion Criteria:

  • active immune modulating (underlying) disease
  • use of immune suppressives
  • use of oral fish oil substrates
  • smoking more than 5 cigarettes/day
  • do not eat more than 5 portions of fatty fish per week

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
Home parenteral nutrition patients
Patients who receive home parenteral nutrition.
Healthy controls
Those who don't receive home parenteral nutrition and consume a normal diet.

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
Essential fatty acid status of plasma phospholipids and peripheral blood mononuclear cells, including the biochemical determination of the Holman index (ratio of mead acid/ arachidonic acid)
Time Frame: On day of blood withdrawal
On day of blood withdrawal

Secondary Outcome Measures

Outcome Measure
Time Frame
Physical examination of clinical signs/symptoms of essential fatty acid deficiency
Time Frame: On day of blood withdrawal
On day of blood withdrawal
Immune function: expression of cell surface markers, stimulus-induced reactive oxygen species production, cytokine production by leukocytes
Time Frame: On day of blood withdrawal
On day of blood withdrawal

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Geert Wanten

Collaborators

Baxter Healthcare Corporation

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2013

Primary Completion (Actual)

November 1, 2014

Study Completion (Actual)

November 1, 2014

Study Registration Dates

First Submitted

November 11, 2013

First Submitted That Met QC Criteria

November 15, 2013

First Posted (Estimate)

November 18, 2013

Study Record Updates

Last Update Posted (Estimate)

November 13, 2014

Last Update Submitted That Met QC Criteria

November 11, 2014

Last Verified

November 1, 2013

More Information

Terms related to this study

Keywords

Other Study ID Numbers

  • 2013/475

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Intestinal Failure

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Malaysia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe